Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Providers
Robert I. Liem, MD, MS

Robert I. Liem, MD

Healthcare Provider
Director of the Comprehensive Sickle Cell Program
Ann & Robert H. Lurie Children's Hospital
Box 30, 225 E Chicago Avenue
Chicago, Illinois, United States

Robert I. Liem is Associate Professor of Pediatrics at Northwestern University, Feinberg School of Medicine. His clinical interests center on hemoglobin disorders, including pediatric and adult sickle cell disease and thalassemia. He is also a clinical investigator with active research programs in these areas. His major research interests focus on exercise responses, inflammation and vascular function as well as their impact on cardiopulmonary fitness, clinical outcomes and physical functioning in children and young adults with sickle cell anemia.

He is also the principal investigator of several other protocols at Lurie Children’s Hospital that are aligned with his interests in exercise physiology, free-living physical activity, habitual exercise patterns and aerobic training in this population. Other areas of clinical and research focus include transition to adult care, patient-centered medical homes, health disparities and parental decision making regarding research participation in sickle cell disease and thalassemia.

 

Representative Publications:

Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease

Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy

Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (MAGiC) study

Association of Sickle Cell Trait With Hemoglobin A1c in African Americans

Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module

Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease

Opioid prescription practices at discharge and 30-day returns in children with sickle cell disease and pain

view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close